Media headlines about Anavex Life Sciences (NASDAQ:AVXL) have been trending positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Anavex Life Sciences earned a news impact score of 0.28 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 44.7432694703604 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Critical Analysis: Anavex Life Sciences (AVXL) vs. Mirati Therapeutics (MRTX) (americanbankingnews.com)
- Anavex Life Sciences (AVXL) Scheduled to Post Quarterly Earnings on Monday (americanbankingnews.com)
- Windtree Therapeutics (WINT) & Anavex Life Sciences (AVXL) Head to Head Analysis (americanbankingnews.com)
- Anavex Life Sciences Corp. (AVXL) Expected to Announce Earnings of -$0.10 Per Share (americanbankingnews.com)
Shares of Anavex Life Sciences (NASDAQ:AVXL) traded down $0.16 during mid-day trading on Monday, hitting $3.58. The company had a trading volume of 281,908 shares, compared to its average volume of 405,758. Anavex Life Sciences has a one year low of $3.33 and a one year high of $6.64.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Week Herald and is owned by of Week Herald. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://weekherald.com/2017/12/04/anavex-life-sciences-avxl-receiving-favorable-press-coverage-report-finds.html.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.